Latest Articlesddd

Why Akebia Therapeutics’ Stock is Outperforming

May 16, 2017 0

AKEBIA THERAPEUTICS? Akebia Therapeutics (AKBA) whose stock trades on the NASDAQ is outperforming. The firm’s drug …

The Value of Sangamo, Merck and AstraZeneca News

May 15, 2017 0

GENE EDITING Sangamo Biosciences: Is it a Comeback? Genome editing allows the creation of therapeutics that …

Who Is the New FDA Commissioner? What Happened to Roche’s Immunotherapy Drug?

May 11, 2017 0

AT A GLANCE IMPORTANT NEWS A New FDA Commissioner The U.S. Senate Voted in Favor of …

Array Biopharma: When Clinical Trial Results Talk

May 10, 2017 0

Positive results were announced from Array’s (ARRY) Part 2 of the Phase 3 COLUMBUS study evaluating …

KITE Pharma: The Risk Versus the Reward

May 9, 2017 0

Indeed, Saving One Life is Important. Yet, Important Too is Saving Many Lives The Risk Vs. …

Why Epizyme’s Upcoming Presentation Is More Than Exciting

May 8, 2017 0

EPIZYME Many oncologists, we believe, must be impatient to learn about the outcome of a first-in-class …

Novartis Agreements with Celyad and Bluebird Bio Say a Lot

May 5, 2017 0

Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD). …

What Makes Merck and Array Shareholders Edgy

May 3, 2017 0

MERCK Merck (MRK) has beaten analysts’ expectations generating $9.4 billion for revenues in the first quarter …

Amgen: A Revolutionary Migraine Product Might Become the First to Reach the Clinic

May 1, 2017 0

MIGRAINE Migraine might have a new potent preventive treatment on the market in the near future. …

ImmunoGen: What About Now?

April 28, 2017 0

ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the …

Prohost Letter #408

April 25, 2017 0

Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the …

Prohost Letter #407

April 20, 2017 0

Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE …

The Market Reaction Towards the FDA Complete Response Letter Offers a Unique Investment Opportunity In Incyte

April 17, 2017 0

Eli Lilly (LLY) and Incyte (INCY) announced that the FDA has issued a complete response letter …

Neurocrine Biosciences: The Meaning of Ingrezza’s Approval for Tardive Dyskinesia (TD)

April 13, 2017 0

On March 27, we wrote about how positive results of Neurocrine Biosciences (NBIX) drug Ingrezza on …

CAR-T Immunotherapy Improvement. A Novel Approach and the Firm Behind It

April 10, 2017 0

CANCER IMMUNOTHERAPY 2 Nonstop Improvements and Nonstop Discoveries In CAR-T Immunotherapy As we said in the …

The FDA Approves Gilead’s HCV Drugs Harvoni and Sovaldi for Adolescents

April 9, 2017 0

The FDA Approves Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis …

Advancements in Cancer Immunotherapy. See Also: A Small Firm with Promising News

April 8, 2017 0

CANCER IMMUNOTHERAPY Nonstop Improvements and Nonstop Discoveries Checkpoint inhibitors and CAR-T immunotherapy are created to stay …

Agenus Reform and Downsizing. Innoviva’s Voting Dilemma

March 30, 2017 0

Agenus (AGEN) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of …

Neurocrine BioSciences (NBIX): Time for Transformation and Achievements

March 27, 2017 0

Positive Results of INGREZZA on Tardive Dyskinesia Highlights Neurocrine Biosciences Sciences and Scientists     The results …

CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

March 23, 2017 0

Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), …